CNC
Centene Corporation
CNC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CNC overall, supported by stronger fundamentals and stronger valuation.
CNC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
CNC's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CNC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $34.05 | -52% |
| Forward | 13x | $70.27 | — |
| Fair | 19x | $57.25 | -19% |
| Current | 23x | $70.27 | — |
| Expensive | 33x | $100 | +43% |
Historical ranges are pointers, not guarantees.
CNC's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CNC in the historical PE scenario, which offers more potential upside but is not a forecast.
CNC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect CNC's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CNC on the outlook, with more favorable revenue expectations.
CNC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.24 | +74% |
| Q3 2026 | $3.01 | +$13.76 |
| Q2 2026 | -$10.35 | -352% |
| Q1 2026 | -$13.05 | -292% |
| Q4 2025 | -$13.53 | -314% |
| Q3 2025 | -$10.75 | -285% |
| Q2 2025 | $4.11 | -23% |
| Q1 2025 | $6.78 | +34% |
| Q4 2024 | $6.31 | +27% |
CNC has returned to profit: it earned $3.01 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CNC on earnings, with more consistent year-over-year improvement.
CNC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.6B | +1.9% |
| Q2 2026 | $53.6B | +9.9% |
| Q1 2026 | $49.9B | +7.1% |
| Q4 2025 | $49.7B | +22% |
| Q3 2025 | $49.7B | +18% |
| Q2 2025 | $48.7B | +22% |
| Q1 2025 | $46.6B | +15% |
| Q4 2024 | $40.8B | +3.4% |
CNC's revenue has grown year over year every quarter since late 2020: $50.6B last quarter, up 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.6% | +13 points |
| Q2 2026 | 2.2% | +3.2 points |
| Q1 2026 | 3.7% | +0.4 points |
| Q4 2025 | -3.5% | -3.9 points |
| Q3 2025 | -14% | -16 points |
| Q2 2025 | -0.9% | -4 points |
| Q1 2025 | 3.3% | +0.5 points |
| Q4 2024 | 0.4% | +0.9 points |
CNC's operating margin was −0.6% last quarter, up 13 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CNC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CNC on profitability, with a higher operating margin.
CNC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9B | -437% |
| Q2 2026 | $3.4B | +117% |
| Q1 2026 | $4.2B | +203% |
| Q4 2025 | $224M | +$965M |
| Q3 2025 | $1.1B | +$2.3B |
| Q2 2025 | $1.6B | -21% |
| Q1 2025 | $1.4B | +$2B |
| Q4 2024 | -$741M | -$735M |
CNC usually generates cash, though not every quarter: the latest was −$3.9B, but it generated $3.9B over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CNC on cash flow, with more consistent year-over-year improvement.
CNC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -3.5M shares |
| 1 year | +0.6% | +3M shares |
| 3 years | -8.7% | -47.1M shares |
| 5 years | -16% | -96.6M shares |
| Available history | -10% | -57.9M shares |
CNC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24M |
| Q2 2026 | $4M |
| Q1 2026 | $29M |
| Q4 2025 | $2M |
| Q3 2025 | — |
| Q2 2025 | $432M |
| Q1 2025 | $41M |
| Q4 2024 | $943M |
CNC spent $59M buying back its own shares over the past year, down 96% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CNC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 1.0x | Healthy |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 0.0x | Very low |
| Q1 2024 | 0.1x | Very low |
| Q4 2023 | 0.2x | Very low |
CNC has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CNC on leverage, with a lower net debt burden relative to earnings.
CNC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 62.6 | Neutral |
CNC's weekly RSI is 64 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CNC PE vs Healthcare Sector
| Metric | CNC | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 9.7% below |
| PE % | 64 | 29 | 35 pts above |
CNC is trading at 23x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CNC on valuation relative to its sector.
CNC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $67.3 | 4.5% above |
| 20 week MA | $66.3 | 5.9% above |
| 50 week MA | $54.3 | 29% above |
| 100 week MA | $51.0 | 38% above |
| 200 week MA | $60.6 | 16% above |
CNC has climbed back above all five of its weekly moving averages, and it's now 16% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CNC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $63.7 | $58.0 | -8.8% |
| 2021 | $58.0 | $84.7 | +46% |
| 2022 | $84.7 | $81.6 | -3.6% |
| 2023 | $81.6 | $74.2 | -9.1% |
| 2024 | $74.2 | $60.6 | -18% |
| 2025 | $60.6 | $40.5 | -33% |
| 2026 YTD | $40.5 | $70.3 | +73% |
CNC has finished four years in a row lower, and it's up 73% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CNC on returns for 2026, with the stronger performance.